Inhibitors of tyrosine kinases and uses thereof

Abstract

Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.

1 .- 26 . (canceled) 
     
     
         27 . A method for treating an autoimmune disease in a subject comprising administering to a subject in need thereof an inhibitor of Bruton's tyrosine kinase (Btk). 
     
     
         28 . The method of  claim 27 , wherein the autoimmune disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, osteoarthritis, lupus, Wegener's granulomatosis, psoriasis, Graves' disease, Sjogren's syndrome, Guillain-Barre syndrome, Addison's disease, or Goodpasture's syndrome. 
     
     
         29 . The method of  claim 27 , wherein the autoimmune disease is rheumatoid arthritis. 
     
     
         30 . The method of  claim 27 , wherein the autoimmune disease is systemic lupus erythematosus. 
     
     
         31 . The method of  claim 27 , wherein the autoimmune disease is Wegener's granulomatosis. 
     
     
         32 . The method of  claim 27 , wherein the autoimmune disease is psoriasis. 
     
     
         33 . A method for treating a heteroimmune condition or disease in a subject comprising administering to a subject in need thereof an inhibitor of Bruton's tyrosine kinase (Btk). 
     
     
         34 . The method of  claim 33 , wherein the heteroimmune condition is graft versus host disease. 
     
     
         35 . The method of  claim 33 , wherein the heteroimmune disease is transplantation. 
     
     
         36 . The method of  claim 33 , wherein the heteroimmune disease is selected from allergies, allergic conjunctivitis, or allergic rhinitis. 
     
     
         37 . A method for treating an inflammatory disease in a subject comprising administering to a subject in need thereof an inhibitor of Bruton's tyrosine kinase (Btk). 
     
     
         38 . The method of  claim 37 , wherein the inflammatory disease is inflammatory bowel disease. 
     
     
         39 . The method of  claim 37 , wherein the inflammatory disease is asthma. 
     
     
         40 . The method of any of  claims 27 ,  33 , and  37 , wherein the inhibitor of Bruton's tyrosine kinase (Btk) is a reversible inhibitor of Btk.